Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/ijms21031102
Keywords
MAPK; ERK; JNK; p38; cancer; drug resistance; combination therapy; metabolism; epigenetics
Funding
- Science Foundation Ireland [18/SPP/3522, 14/IA/2395]
- Science Foundation Ireland (SFI) [14/IA/2395] Funding Source: Science Foundation Ireland (SFI)
Ask authors/readers for more resources
Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous signal transduction pathways that regulate all aspects of life and are frequently altered in disease. Here, we focus on the role of MAPK pathways in modulating drug sensitivity and resistance in cancer. We briefly discuss new findings in the extracellular signaling-regulated kinase (ERK) pathway, but mainly focus on the mechanisms how stress activated MAPK pathways, such as p38 MAPK and the Jun N-terminal kinases (JNK), impact the response of cancer cells to chemotherapies and targeted therapies. In this context, we also discuss the role of metabolic and epigenetic aberrations and new therapeutic opportunities arising from these changes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available